Table 2.
Cell lines from ovarian endometrioid adenocarcinoma
| Cell line | Age | Materials | Chromosome Number | DT | Transplantability | Immunotaining | Characteristics |
|---|---|---|---|---|---|---|---|
| #2774 (1978) |
- |
ascites |
66-68 |
- |
Yes |
- |
- |
| - (1983) |
47 |
ascites |
103 (51–402) |
74.4 |
Yes |
- |
- |
| OVK18 (1983) |
49 |
ascites |
47 (mode) |
48 |
Yes |
- |
ER(−), PgR(−) |
| HMOA (1986) |
57 |
ovarian tumor |
46-47 (mode) |
72, 58 |
Yes |
- |
production of CA125 |
| HNOA (1986) |
71 |
transplanted tumor |
46-47 (mode) |
28, 24 |
Yes |
- |
CA125(−) |
| HOC-I (1989) |
40 |
recurrent tumor |
46 (44–49) |
75 |
Yes |
ER(−) |
ER(−), production of CA125, TPA |
| COV362 (1993) |
- |
- |
69 (67–73) |
- |
- |
- |
- |
| SIB-1 (1994) |
39 |
pleural effusion |
46 (43–54) |
- |
- |
HMFG-2, CA125 |
serum free medium |
| SNU-251 (1997) |
47 |
ascites |
- |
46 |
- |
- |
CA125(−), CEA(−), p53, BRCA1, hMLH1 mutation(+) |
| SNU-563 (1997) |
54 |
ovarian tumor |
- |
67 |
- |
- |
p53 mutation(+) |
| NOE (2007) |
46 |
tumor fluid |
65-74 |
- |
Yes |
- |
ER(+) |
| NOMH-1 | 44 | ovarian tumor | 73-80 | 273 | Yes | CA19-9, CEA, ER(−), PgR(−) | production of CA19-9, CEA, TPA |
DT; doubling time (hour).